Decision on Elan subsidiary delayed

A DECISION regarding the future status of Elan’s drug-delivery business – Elan Drug Technologies (EDT) – may not be made until next year.

Last month, the Dublin-headquartered pharmaceutical firm announced it was re-examining the possibility of separating its Athlone-based subsidiary from the main group in order to give it a necessary injection of fresh investment.

It stressed that when it considered something similar in 2008, the idea was purely financially driven; but that since Johnson & Johnson invested in the company last year, such a move for EDT would now be based on the strategic benefits.